<DOC>
	<DOCNO>NCT02983708</DOCNO>
	<brief_summary>The current study describes randomize , double-blind , cross-over study intravenous G-CSF follow infusion autologous mobilize peripheral blood mononuclear cell ( mPBMCs ) child cerebral palsy ( CP ) determine safety feasibility procedure , well potential efficacy improve neurological impairment .</brief_summary>
	<brief_title>Neuroregenerative Potential Intravenous G-CSF Autologous Peripheral Blood Stem Cells</brief_title>
	<detailed_description>We hypothesize mobilized peripheral blood mononuclear cell ( mPBMCs ) would better source cell therapy child CP , cell similar neuroregenerative potential bone marrow/cord blood mononuclear cell ( MNCs ) . Multipotent precursor cell exist peripheral blood , fraction elutriated blood cell normal individual contain MNCs potential MSCs . There several advantage use mPBMCs cell therapy child CP : G-CSF use mPBMCs neuroregenerative potential ; collection fractionation stem cell repeat ; , therapy suitable child CP .</detailed_description>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Non severe type cerebral palsy Evidences abnormal MRI finding periventricular leukomalacia Collected mobilize peripheral blood mononuclear cell count &gt; 1×10^8/kg CD34+ cell count &gt; 1×10^6/kg Consent form Previous trial autologous cord blood infusion erythropoietin/GCSF Chromosomal abnormality</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Neuroregeneration</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Peripheral blood mononuclear cell</keyword>
	<keyword>Cerebral palsy</keyword>
</DOC>